-
1 week ago | 
oncologynewscentral.com | Robert A. Winn |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Welcome, this is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. I’m delighted to visit with Bob Winn, who is the director and Lipman Chair in Oncology at VCU Massey Cancer Center and current president of the Association of American Cancer Institutes. Bob, thanks for joining us. Robert A. Winn, MD: Thank you for having me.
-
1 week ago | 
oncologynewscentral.com | Yelena Y. Janjigian |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Hello, this is Bob Figlin, the Steven Spielberg Family chair in Hematology-Oncology at Cedars-Sinai Cancer in Los Angeles. And I’m delighted to have Dr. Yelena Janjigian, who is the chief of the Gastrointestinal Oncology service at Memorial Sloan Kettering (MSK) Cancer Center in New York City. Yelena, thanks so much for joining us today. Yelena Y. Janjigian, MD: It’s such an honor, Bob. Thanks so much for having me.
-
2 weeks ago | 
oncologynewscentral.com | William Gradishar |Robert A. Figlin
Data from the SERENA-6 trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting, have the potential to dramatically change advanced estrogen receptor–positive, HER2-negative breast cancer care, says William J Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine in Chicago. The study showed benefit in switching therapies based on circulating tumor DNA evidence of ESR1 mutation, ahead of disease progression.
-
2 weeks ago | 
oncologynewscentral.com | Stephanie Graff |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Good morning, this is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles. And I’m delighted to welcome Stephanie Graff, who is the director of breast oncology at the Brown University Health Cancer Institute. Welcome. Stephanie Graff, MD: Thanks for having me. Dr. Figlin: So, it’s amazing that things continue to change so dramatically in breast cancer.
-
2 weeks ago | 
oncologynewscentral.com | Jonathan Rosenberg |Robert A. Figlin
“For the first 15 years of my career, we had nothing new” in bladder cancer care, said Jonathan E. Rosenberg, MD, chief of the genitourinary oncology service at Memorial Sloan Kettering Cancer Center in New York City. Now, “the pace of change has been dizzying,” he told Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology.
-
3 weeks ago | 
oncologynewscentral.com | W. Kimryn Rathmell |Robert A. Figlin
“Is it time to do something big and different? That’s always a good question to ask,” said W. Kimryn Rathmell, MD, PhD, MMHC, the immediate former director of the National Cancer Institute (NCI) and the current CEO of The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute. At the 2025 American Society of Clinical Oncology Annual Meeting, Dr. Rathmell spoke with Robert A.
-
3 weeks ago | 
oncologynewscentral.com | Andrew Kuykendall |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Good afternoon. This is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology and the cancer center director at Cedars-Sinai Cancer in Los Angeles. And I'm absolutely delighted to have Andrew Tucker Kuykendall, who is a member of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa. Andrew, welcome. Andrew Kuykendall, MD: Thank you so much. Dr. Figlin: It's a big day.
-
3 weeks ago | 
oncologynewscentral.com | Jason Aboudi Mouabbi |Robert A. Figlin
This transcript has been lightly edited for style and clarity. Robert A. Figlin, MD: Hello. This is Bob Figlin, the Steven Spielberg Family Chair in Hematology Oncology and cancer center director at Cedars-Sinai Cancer in Los Angeles. And I’m delighted today to be joined by Jason Mouabbi, who is in the Department of Breast Medical Oncology at MD Anderson at the University of Texas in Houston. Jason, thanks for joining us today. Jason Aboudi Mouabbi, MD: Thank you for having me.
-
1 month ago | 
oncologynewscentral.com | VK Gadi |Robert A. Figlin
The approach to ESR1 and PIK3CA mutations in patients with hormone receptor–positive metastatic breast cancer continues to evolve. What role does circulating tumor DNA (ctDNA) play in treatment decisions? How should oncologists best approach patients with PIK3CA mutations who subsequently develop ESR1 mutations? VK Gadi, MD, PhD, professor and director of medical oncology and deputy director of the University of Illinois Cancer Center in Chicago, discusses with Robert A.
-
2 months ago | 
oncologynewscentral.com | Youssef Rddad |Manali Bhave |Robert A. Figlin |Stephanie Graff
This transcript has been lightly edited for clarity. Robert A. Figlin, MD, FACP: Hello, this is Bob Figlin, the Cancer Center Director at Cedars-Sinai Cancer and the Steven Spielberg Family Chair in Hematology-Oncology. And I’m absolutely delighted to have back Erika Hamilton, who is the director of breast cancer and gynecologic cancer research at Sarah Cannon in Nashville, and a past chair of the American Society of Clinical Oncology (ASCO) Scientific Breast Committee. Erika, welcome.
